Biphasic insulin aspart 30/70 was administered once, twice or three-times daily, depending on the patient's needs; the dose was adjusted individually as required, based on the physician's decision ...

Potential Weakness: The potential weakness of the studies is that they were of relatively short duration (≤24 weeks) and so the long-term effects of insulin aspart in CSII cannot be assessed.

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart. Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and ...